Biohaven And Yale University Announce Federal Jury Verdict In Their Favor In Trade Secret Misappropriation And Breach Of Contract Litigation Against Avilar Therapeutics And RA Capital
The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade secret relating to its "MODA" targeted protein degradation platform, and that RA Capital separately breached its
A jury said Avilar and RA Capital wrongly used Biohaven's secret technology without permission. This is a win for Biohaven, though it doesn't change their actual medicine or business—just protects their ideas from being copied.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.